Veritable’s Lineage Cell Therapeutics LCTX Stock Holding History

Veritable’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-124,124	Closed	-$233K	–	816
2017 Q4	$233K	Hold	124,124	–	–	﹤0.01%	715
2017 Q3	$308K	Sell	124,124 -17,728	-12%	-$44K	0.01%	606
2017 Q2	$391K	Sell	141,852 -35,456	-20%	-$99.1K	0.01%	562
2017 Q1	$535K	Hold	177,308	–	–	0.01%	474
2016 Q4	$560K	Hold	177,308	–	–	0.01%	446
2016 Q3	$605K	Hold	177,308	–	–	0.02%	420
2016 Q2	$405K	Hold	177,308	–	–	0.01%	495
2016 Q1	$445K	Sell	177,308 -14,894	-8%	-$33.2K	0.01%	477
2015 Q4	$636K	Hold	192,202	–	–	0.02%	404
2015 Q3	$465K	Buy	192,202 +92,926	+94%	+$241K	0.01%	466
2015 Q2	$291K	Sell	99,276 -3,097	-3%	-$12K	0.01%	607
2015 Q1	$411K	Hold	102,373	–	–	0.01%	656
2014 Q4	$308K	Buy	+102,373	New	+$277K	0.01%	737

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Veritable's LCTX Position: Q1 2018 in Review

Veritable sold out of Lineage Cell Therapeutics (LCTX) in Q1 2018, closing a stake of 124,124 shares — an estimated $233K sold.

Veritable first reported a position in LCTX in Q4 2014 and held it in 13 quarters. The position peaked at $636K in Q4 2015. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2018.

Veritable reported no remaining Lineage Cell Therapeutics position as of Q1 2018 after selling out during the quarter.
Veritable sold 124,124 Lineage Cell Therapeutics shares in Q1 2018, an estimated $233K.
Veritable first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 13 quarters.
Veritable's Lineage Cell Therapeutics position peaked at $636K in Q4 2015.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2018.

Based on Veritable's 13F filing for Q1 2018, filed 14 May 2018.